Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GPR183 | P32249 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1002845 | 0.93 | AVPR1A (0.39) | AVPR1AUSP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL4072383 | 0.81 | AVPR1A (0.38) | AVPR1AUSP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL4074130 | 0.81 | CRBN (0.39) | AVPR1AUSP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL4067697 | 0.79 | CRBN (0.40) | AVPR1AUSP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL21843465 | 0.77 | USP2 (0.49) | AVPR1AUSP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL17324893 | 0.74 | SIGMAR1 (0.45) | USP2SMN1; SMN2DDB1CRBNACACB | |
| SCHEMBL31170164 | 0.70 | USP30 (0.51) | USP2SMN1; SMN2DDB1CRBNTSHR | |
| SCHEMBL25967353 | 0.70 | USP2 (0.43) | USP2SMN1; SMN2ACACBTSHRGPR183 | |
| SCHEMBL22814430 | 0.70 | USP2 (0.46) | AVPR1AUSP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL16914415 | 0.70 | USP2 (0.50) | AVPR1AUSP2SMN1; SMN2DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247560-A1 | Diaryl ketimine derivative | BANYU PHARMACEUTICAL CO., LTD. | 2009-10-01 | — | — | US | disclosed |
| EP-2072519-A1 | DIARYL KETIMINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247560-A1 | Diaryl ketimine derivative | NR0B2, NR2C2, NR3C2 | AVPR1A 364/4885USP2 2701/4885SMN1; SMN2 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.